(top 60%)
Impact Factor
(top 60%)
extended IF
89(top 4%)
H-Index
426
authors
3.4K
papers
58K
citations
4K
citing journals
13.2K
citing authors

Most Cited Articles of European Journal of Nuclear Medicine and Molecular Imaging

TitleYearCitations
Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients19931.3K
Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands2001487
Fluorine-18 deoxyglucose and false-positive results: a major problem in the diagnostics of oncological patients1996418
[177Lu-DOTAOTyr3]octreotate: comparison with [111In-DTPAo]octreotide in patients2001392
Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose1996386
Nitroimidazoles and imaging hypoxia1995317
Attention deficit hyperactivity disorder: binding of [99mTc]TRODAT-1 to the dopamine transporter before and after methylphenidate treatment2000241
Relationships between oesophageal transit and solid and liquid gastric emptying in diabetes mellitus1991238
Partition model for estimating radiation doses from yttrium-90 microspheres in treating hepatic tumours1996237
FDG-PET for clinical use. Results of the 3rd German Interdisciplinary Consensus Conference, "Onko-PET III", 21 July and 19 September 20002001230
FDG-PET for detection of osseous metastases from malignant primary bone tumours: comparison with bone scintigraphy2000229
Dual time point fluorine-18 fluorodeoxyglucose positron emission tomography: a potential method to differentiate malignancy from inflammation and normal tissue in the head and neck1999222
Sr-89 therapy: strontium kinetics in disseminated carcinoma of the prostate1986202
18F-DOPA positron emission tomography for tumour detection in patients with medullary thyroid carcinoma and elevated calcitonin levels2001198
The clinical benefit of imaging striatal dopamine transporters with [123I]FP-CIT SPET in differentiating patients with presynaptic parkinsonism from those with other forms of parkinsonism2001198
First experience in healthy volunteers with technetium-99m L,L-ethylenedicysteine, a new renal imaging agent1993198
Fluorine-18 deoxyglucose uptake in sarcoidosis measured with positron emission tomography1994193
Fluorine-18 2-deoxy-2-fluoro-D-glucose PET in the preoperative staging of breast cancer: comparison with the standard staging procedures2001190
Advantage of delayed whole-body FDG-PET imaging for tumour detection2001189
Clinical evaluation of the partition model for estimating radiation doses from yttrium-90 microspheres in the treatment of hepatic cancer1997185
Recent progress in fluorine-18 labelled peptide radiopharmaceuticals2001180
Imaging of dopamine transporters in humans with technetium-99m TRODAT-11996180
Experience with carbon-11 choline positron emission tomography in prostate carcinoma2000177
Somatostatin receptor-mediated imaging and therapy: basic science, current knowledge, limitations and future perspectives2001171
Fluorine-18 fluorodeoxyglucose positron emission tomography in the differential diagnosis of pancreatic carcinoma: a report of 106 cases1997168